Неалкогольная жировая болезнь печени и кардиоваскулярные риски
https://doi.org/10.51922/2616-633X.2023.7.2.1991
Аннотация
Неалкогольная жировая болезнь печени – это многофакторное заболевание со сложным механизмом развития, которое ассоциировано с нарушениями обмена веществ, функции различных органов и систем, а также с возникновением ряда заболеваний, в частности, атеросклероза. По данным научных исследований, проведенных в последние годы, неалкогольная жировая болезнь печени является предиктором неблагоприятных сердечно-сосудистых событий и может выступать самостоятельным фактором риска развития болезней системы кровообращения, независимо от наличия сахарного диабета, дислипидемии или ожирения. Цель настоящей работы – провести анализ опубликованных научно-исследовательских данных по эпидемиологии, этиопатогенезу, диагностике и особенностям клинического течения неалкогольной жировой болезни печени у пациентов с болезнями системы кровообращения; охарактеризовать современное состояние проблемы, определить направление проведения дальнейших исследований.
Ключевые слова
При поддержке: Исследование проводится в рамках задания НИОК(Т)Р «Распространенность и факторы, ассоциированные с нарушениями костно-мышечного статуса, у пациентов молодого и среднего возраста с артериальной гипертензией и неалкогольной жировой болезнью печени в российской и белорусской популяциях» совместно с ФГБУ «НМИЦ ТПМ» Минздрава России. № гос. регистрации 20221914 от 27.12.2022.
Список литературы
1. Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V.T., Tkacheva O.N., Troshina E.A., Shestakova M.V., Breder V.V., Geyvandova N.I., Doshchitsin V.L., Dudinskaya E.N., Ershova E.V., Kodzoeva Kh.B., Komshilova K.A., Korochanskaya N.V., Mayorov A.Yu., Mishina E.E., Nadinskaia M.Yu., Nikitin I.G., Pogosova N.V., Tarzimanova A.I., Shamkhalova M.Sh. Nacionalnyj konsensus dlya vrachej po vedeniyu vzroslyh pacientov s nealkogolnoj zhirovoj bolezn’yu pecheni i ee osnovnymi komorbidnymi sostoyaniyami [The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities]. Ter Arkhiv, 2022, vol. 94, no. 2, рр. 216–253. doi: 10.26442/00403660.2022.02.201363. (in Russian).
2. Younossi Z.M., Koenig A.B., Abdelatif D., et al. Global Epidemiology of Nonalcoho-lic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology. 2016, vol 64, no. 1, pp. 73-84. doi: 10.1002/hep.28431.
3. Drapkina O.M., Ivashkin V.T. Epidemiologicheskie osobennosti nealkogolnoj zhirovoj bolezni pecheni v rossii (rezultaty otkrytogo mnogocentrovogo prospektivnogo issledovaniya-nablyudeniya DIREG L 01903) [Epidemiologic features of non- alcoholic fatty liver disease in Russia (Results of open multicenter prospective observational study DIREG L 01903)]. Russ J Gastroenterol Hepatol Coloproctiol, 2014, vol. 24, no. 4, pp. 32–38. (in Russian).
4. Evstifeeva S.E., Shalnova S.A., Kutsenko V.A., Yarovaya E.V., Balanova Yu.A., Imaeva A.E., Kapustina A.V., Muromtseva G.A., Maksimov S.A., Karamnova N.S., Soplenkova A.G., Filichkina E.M., Viktorova I.A., Prishchepa N.N., Redko A.N., Yakushin S.S., Drapkina O.M. Rasprostranennost nealkogolnoj zhirovoj bolezni pecheni sredi naseleniya trudosposobnogo vozrasta: associacii s socialno-demograficheskimi pokazatelyami i povedencheskimi faktorami riska (DANNYE ESSE-RF-2) [Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data)]. Kardiovaskulyarnaya terapiya i profilaktika. 2022, vol. 21, no 9, pp. 40–49. doi: 10.15829/1728-8800-2022-3356 (in Russian).
5. Younossi Z.M., Stepanova M., Afendy M., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol, 2011, vol. 9, no. 6, pp. 524–530. doi: 10.1016/j.cgh.2011.03.020.
6. Day C.P., James O.F. Steatohepatitis: a tale of two “hits”? Gastroenterology, 1998, vol. 114, pp. 842–845. doi: 10.1016/s0016-5085(98)70599-2.
7. Xian Y.X., Weng J.P., Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J. 2020, vol. 134, pp. 8 doi: 10.1097/ CM9.0000000000001263.
8. Wu Y., Zheng Q., Zou B., Yeo Y.H., Li X., Li J., et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatol Int, 2020, vol. 12, pp. 259–269. doi: 10.1007/s12072-020-10023-3.
9. Maev I.V., Andreev D.N., Kucheryavyy Yu.A. Prevalence of non-alcoholic fat disease liver in Russian Federation: meta-analysis. Consilium Medicum, 2023, vol. 25, no. 5, pp. 313–319. doi: 10.26442/20751753.2023.5.202155.
10. Le M.H., Yeo Y.H., Li X., et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 2022, vol. 20, no. 12, pp. 2809-2817. doi: 10.1097/HC9.0000000000000244.
11. Younossi Z.M., Golabi P., Paik J.M., et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology, 2023, vol. 77, no. 4, pp. 1335-1347. doi: 10.1097/HEP.0000000000000004.
12. Kotovskaya Yu.V. Non-alcoholic fatty liver disease and cardiovascular risks: A review. Consilium Medicum, 2023, vol. 25, no. 4, pp. 253–258. doi: 10.26442/20751753.2023.4.202275.
13. Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal, F., Romero D., et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023. doi: 10.1097/HEP.0000000000000520.
14. Eslam M., Sanyal A.J., George J., Sanyal A., Neuschwander-Tetri B., Tiribelli C., et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020, vol. 158, pp. 1999–2014. doi: 10.1053/j.gastro.2019.11.312.
15. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020, vol. 7, pp. 202–209. doi: 10.1016/j.jhep.2020.03.039.
16. Pakhomova I.G., Knorring G.Yu. Nealkogolnaya zhirovaya bolezn’ pecheni i serdechno-sosudistaya patologiya: osobennosti vedeniya pacienta na klinicheskom primere [Non-alcoholic fatty liver disease and cardiovascular pathology: features of patient management on a clinical example]. Experimental Clin Gastroenterology, 2022, no. 9(205), pp. 290–297. doi: 10.31146/1682-8658-ecg-205-9-290-297. (in Russian).
17. Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Kotovskaya Yu.V., Tkacheva O.N., Troshina E.A., Shestakova M.V., Maev I.V., Breder V.V., Gheivandova N.I., Doshchitsin V.L., Dudinskaya E.N., Ershova E.V., Kodzoeva Kh.B., Komshilova K.A., Korochanskaya N.V., Mayorov A.Yu., Mishina E.E., Nadinskaya M.Yu., Nikitin I.G., Pogosova N.V., Tarzimanova A.I., Shamkha-lova M.Sh. Klinicheskie rekomendacii Rossijskogo obshchestva po izucheniyu pecheni, Rossijskoj gastroenterologicheskoj associacii, Rossijskoj associacii endokrinologov, Rossijskoj associacii gerontologov i geriatrov i Nacionalnogo obshchestva profilakticheskoj kardiologii po diagnostike i lecheniyu nealkogolnoj zhirovoj bolezni pecheni [Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease]. Russ J Gastroenterol Hepatol Coloproctiol, 2022, vol. 32, no 4, pp. 104–140. doi: 10.22416/1382-4376-2022-32-4-104-140. (in Russian).
18. Pavlov Ch.S., Kuznetsova Е.A., Arslanyan M.G., Semenistaya M.Ch., Glushenkov D.V., Nikolenko V.N. Nealkogolnaya zhirovaya bolezn pecheni: sovremennye koncepcii etiologii, patogeneza, diagnostiki i lecheniya [Non-alcoholic fatty liver disease: modern concepts of etiology, pathogenesis]. Med Vestn Severnogo Kavkaza, 2017, vol. 12, no. 2, pp. 230-234. doi: 10.14300/mnnc.2017.1206.
19. Drapkina O.M., Yafarova A.A. Nealkogolnaya zhirovaya bolezn pecheni i serdechno-sosudistyj risk: sostoyanie problemy [Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk: Scientific Problem State]. Rat Pharmacother Cardiology, 2017, vol. 13, no. 5, pp. 645-650. doi: 10.20996/1819-6446-2017-13-5-645-650. (in Russian).
20. Lambert J.E., Ramos-Roman M.A., Browning J.D., Parks E.J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fat-ty liver disease. Gastroenterology, 2014, vol. 146, pp. 726–35. doi: 10.1053/j.gastro.2013.11.049.
21. Younossi Z. Global epidemiology of nonalcoholic fatty liver desease – Meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2016, vol. 64, pp. 73–84. doi: 10.1002/hep.28431.
22. Zhou Y.Y., Zhou X.D., Wu S.J., Fan D.H., Van Poucke S., Chen Y.P., Fu S.W., Zheng M.H. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A syste- matic review and meta-analysis. Hepatol Commun, 2018, vol. 2, pp. 376–392. doi: 10.1002/hep4.115.
23. Mantovani A., Dauriz M., Sandri D., Bonapace S., Zoppini G., Tilg H., Byrne C.D., Targher G. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. Liver Int, 2019, vol. 39, pp. 758–769. doi: 10.1111/liv.14044.
24. Cai X., Zheng S., Liu Y., Zhang Y., Lu J., Huang Y. Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation. Liver Int, 2020, vol. 40, pp. 1594–1600. doi: 10.1111/liv.14461.
25. Wijarnpreecha K., Lou S., Panjawatanan P., Cheungpasitporn W., Pungpapong S., Lukens F.J., Ungprasert P. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Dig Liver Dis, 2018, vol. 50, pp. 1166–1175. doi: 10.1016/j.dld.2018.09.004.
26. Cheungpasitporn W., Ungprasert P. Association between cardiac conduction defect and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Gastroenterol, 2020, vol. 33, pp. 661–666. doi: 10.20524/aog.2020.0535.
27. Di Minno M.N., Di Minno A., Ambrosino P., Songia P., Tremoli E., Poggio P. Aortic valve sclerosis as a marker of atherosclerosis: novel insights from hepatic steatosis. Int J Cardiol, 2016, vol. 217, pp. 1–6. doi: 10.1016/j.ijcard.2016.04.162.
28. Muzurović E., Peng C.C., Belanger M.J., Sanoudou D., Mikhailidis D.P., Mantzoros C.S. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. Hypertension. 2022, vol. 79, no 7, pp. 1319-1326. doi: 10.1161/HYPERTENSIONAHA.122.17982.
29. Oikonomou D., Georgiopoulos G., Katsi V., Kourek C., Tsioufis C., Alexopoulou A., Koutli E., Tousoulis D. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated? Eur J Gastroenterol Hepatol. 2018, vol. 30, pp. 979–985. doi: 10.1097/MEG.0000000000001191.
30. Donati G., Stagni B., Piscaglia F., Venturoli N., Morselli-Labate A.M., Rasciti L., Bolondi L. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut, 2004, vol. 53, no 7, pp. 1020-3. doi: 10.1136/gut.2003.027086.
31. Zhao Y.C., Zhao G.J., Chen Z., She Z.G., Cai J., Li H. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension. Hypertension, 2020, vol. 75, no 2, pp. 275-284. doi: 10.1161/HYPERTENSIONAHA.119.13419.
32. Ma J., Hwang S.J., Pedley A., Massaro J.M., Hoffmann U., Chung R.T., Benjamin E.J., Levy D., Fox C.S., Long M.T. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol, 2017, vol. 66, pp. 390–397. doi: 10.1016/j.jhep.2016.09.022.
33. Targher G., Bertolini L., Rodella S., Tessari R., Zenari L., Lippi G., Arcaro G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care, 2007, vol. 30, no. 8, pp. 2119–2121. doi: 10.2337/dc07-0349.
34. Mahfood H.T., Hamdeh S., Kanmanthareddy A., Alla V.M. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes Metab Syndr, 2017, vol. 11, no. 1, pp. 209-S216. doi: 10.1016/j.dsx.2016.12.033.
35. Targher G., Byrne C.D., Lonardo A., Zoppini G., Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol, 2016, vol. 65, no. 3, pp. 589–600. doi: 10.1016/j.jhep.2016.05.013.
Рецензия
Для цитирования:
Антюх К.Ю. Неалкогольная жировая болезнь печени и кардиоваскулярные риски. Неотложная кардиология и кардиоваскулярные риски. 2023;7(2):1991-1999. https://doi.org/10.51922/2616-633X.2023.7.2.1991
For citation:
Antyukh K. Non-alcoholic fatty liver disease and cardiovascular risks. Emergency Cardiology and Cardiovascular Risks journal. 2023;7(2):1991-1999. (In Russ.) https://doi.org/10.51922/2616-633X.2023.7.2.1991
Просмотров:
4
Послать статью по эл. почте 